Tesaro 3000-01-002- Phase 1B Dose-Finding Study Of Niraparib, Tsr-022, Bevacizumab, And Platinum-Based Doublet Chemotherapy In Combination With Tsr-042 In Patients With Advanced Or Metastatic Cancer
Posted Date: Jun 10, 2019
- Investigator: Muhammad Riaz
- Specialties: Cancer, Oncology
- Type of Study: Drug
To evaluate the safety and tolerability of Niraparib, TSR-022, Bevacizumab and Platinum-Based Doublet Chemotherapy in combination with TSR-042 in patients with advanced or metastatic cancer.
Criteria:
Over 18 Years Of Age, Previously Treated For Advanced Or Metastatic Cancer, Not Pregnant.
Keywords:
Metastatic Cancer, Advanced Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com